Skip to content

Tranexamic Acid : Nebulization vs IV Route for Hemoptysis

Tranexamic Acid : Nebulization vs IV Route for Hemoptysis

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07212452
Enrollment
172
Registered
2025-10-08
Start date
2025-08-01
Completion date
2025-10-31
Last updated
2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoptysis, NEBULIZATION, Tranexamic Acid

Keywords

Hemoptysis, Nebulization, tranexamic acid

Brief summary

This study compares the effect of tranexamic acid on hemoptysis when given through the conventional IV route and Through nebulization.

Detailed description

The investigators are conducting a randomized controlled trial for the comparison of routes through which tranexamic acid can be given to control hemoptysis. The study participants will be divided into 2 groups randomly and 1 group will be assigned to use IV route while other will be assigned the nebulization route and the result variables include the time taken for complete control of hemoptysis and recurrence time. Another variable is the reduction in amout of blood in sputum after each intervention.

Interventions

DRUGTranexamic Acid (TXA)

In this study we are comparing the effect of tranexamic acid on hemoptysis when given through IV route and nebulization

Sponsors

University of Health Sciences Lahore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

There is no masking as the participnats will be explained the whole process and consent would be taken for using the either route for administration of tranexamic acid

Intervention model description

The intervention will be given to the participants via providing the tranexamic acide through both IV and nebulization routes.

Eligibility

Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with mild to moderate hemoptysis \< 600ml/ 24 hours of age 12 to 80 years and both genders. 2. Patients with hemoptysis due to infective pathology. 3. Patients with hemoptysis due to malignant pathology.

Exclusion criteria

1. Patients on antiplatelet therapy or aspirin 2. Hemoptysis after penetrating lung injury e.g. firearm injury 3. Patients with history of asthma

Design outcomes

Primary

MeasureTime frameDescription
Time to control hemoptysis48 hoursIn this study the time taken by tranexamic acid to acehive comolete control of hemoptysis will be compared when given through IV and nebulization.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026